Welcome to our dedicated page for Nutex Health SEC filings (Ticker: NUTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how every new Nutex Health micro-hospital impacts revenue, or how its risk-bearing population health contracts alter margins, means wading through dense reimbursement codes and capitation footnotes. Nutex Health SEC filings explained simply is what most investors search for, yet the company’s 300-page 10-K and frequent 8-K updates make that anything but simple.
Stock Titan solves the problem. Our platform delivers AI-powered summaries for each Nutex Health annual report 10-K simplified, every Nutex Health quarterly earnings report 10-Q filing, and each Nutex Health 8-K material events explained in plain language. Real-time feeds push Nutex Health Form 4 insider transactions real-time to your dashboard, letting you monitor Nutex Health executive stock transactions Form 4 minutes after they hit EDGAR. You’ll also find quick answers to common questions like “What does Nutex Health report in its proxy statement executive compensation?” or “Where can I see Nutex Health insider trading Form 4 transactions?”—all in one place.
Dive deeper with interactive tools that connect filing sections to what matters: facility count growth, payer-mix shifts, technology platform costs, and segment EBITDA. Whether you need Nutex Health earnings report filing analysis before the call, understanding Nutex Health SEC documents with AI for due diligence, or an alert when a director buys shares, our expert analysis and comprehensive coverage remove the hours of manual work. Stay ahead with real-time updates on every filing type, from S-8 share registrations to the latest Nutex Health proxy statement executive compensation details, and make confident decisions faster.
Nutex Health (NUTX)Wesley Shane Bamburg. The filing states that no securities are beneficially owned by the reporting person as of the event date.
The event date is 10/15/2025, and the form was filed by one reporting person. This is a routine Section 16 initial ownership report confirming no current holdings.
Nutex Health Inc. filed an 8‑K announcing it issued a press release with anticipated preliminary financial metrics for the period ended September 30, 2025, furnished as Exhibit 99.1.
The company also updated its Nasdaq listing status. Nutex is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to not timely filing its Quarterly Report on Form 10‑Q for the period ended June 30, 2025. The company submitted a compliance plan on October 15, 2025, and Nasdaq granted an extension on October 16, 2025 to file the June 30, 2025 Form 10‑Q by December 12, 2025. If Nutex does not file by December 12, 2025, Nasdaq staff will issue a delisting notice, which the company may appeal to a Nasdaq Hearings Panel.
Nutex Health, Inc. appointed Michael Bamburg as Chief Operating Officer and disclosed the principal terms of his employment agreement dated September 16, 2025. Bamburg, age 43, joins from HCA Houston Healthcare with a background in payor contracting and provider operations and holds a B.S. in Healthcare Administration and an MBA. The two-year agreement provides a base salary of $415,000 with automatic two-year extensions unless timely notice is given, eligibility for an annual cash bonus up to 60% of base salary, participation in long-term incentive awards valued up to 60% of base salary if granted, and a $100,000 signing bonus payable over four quarters if he remains employed at least 12 months. The agreement includes twelve months' severance and health subsidy if terminated without cause or for good reason, and standard accrual and reimbursement provisions. The filing incorporates the full agreement as Exhibit 10.1.
Nutex Health, Inc. appointed Michael L. Reed as Lead Independent Director effective
FAQ
What is the current stock price of Nutex Health (NUTX)?
What is the market cap of Nutex Health (NUTX)?
